Avidity Biosciences (RNA) Stock Forecast & Price Target

$31.88 -1.42 (-4.26%)

As of 01:57 PM Eastern

Avidity Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
0

Buy
13

Based on 13 Wall Street analysts who have issued ratings for Avidity Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 13 have given a buy rating for RNA.

Consensus Price Target

$66.69
109.20% Upside

According to the 13 analysts' twelve-month price targets for Avidity Biosciences, the average price target is $66.69. The highest price target for RNA is $96.00, while the lowest price target for RNA is $48.00. The average price target represents a forecasted upside of 109.20% from the current price of $31.88.

Get the Latest News and Ratings for RNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors.

RNA Analyst Ratings Over Time

Type	Current Forecast 3/25/24 to 3/25/25	1 Month Ago 2/24/24 to 2/23/25	3 Months Ago 12/26/23 to 12/25/24	1 Year Ago 3/26/23 to 3/25/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	10 Buy rating(s)	11 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$66.69	$65.80	$64.36	$36.33
Forecasted Upside	109.20% Upside	111.44% Upside	105.31% Upside	56.68% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Remove Ads

RNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Avidity Biosciences Stock vs. The Competition

Type	Avidity Biosciences	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.54
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	100.28% Upside	21,088.52% Upside	16.92% Upside
News Sentiment Rating	Neutral News See Recent RNA News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/17/2025	Needham & Company LLC 2 of 5 stars	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00	+83.06%
3/17/2025	HC Wainwright 1 of 5 stars	A. Ghosh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00	+124.71%
3/17/2025	Chardan Capital 1 of 5 stars	K. Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00	+107.89%
3/13/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00	+114.66%
3/12/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$72.00	+143.41%
3/10/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$51.00 ➝ $48.00	+58.82%
3/7/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$70.00	+130.64%
2/28/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$63.00 ➝ $57.00	+86.03%
1/21/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $67.00	+120.24%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$56.00 ➝ $78.00	+68.69%
Get the Latest News and Ratings for RNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.
9/24/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$59.00	+35.63%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00 ➝ $96.00	+132.11%
8/26/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Clark-Gartner Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$54.00 ➝ $53.00	+21.12%
1/3/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$50.00	+422.47%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$30.00	+220.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:48 PM ET.

RNA Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Avidity Biosciences is $66.69, with a high forecast of $96.00 and a low forecast of $48.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNA shares.
: According to analysts, Avidity Biosciences's stock has a predicted upside of 109.20% based on their 12-month stock forecasts.
: Avidity Biosciences has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Chardan Capital, Citigroup, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, and Scotiabank in the past 90 days.
: Analysts like Avidity Biosciences more than other "medical" companies. The consensus rating for Avidity Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:RNA) was last updated on 3/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Stock Forecast & Price Target